Assetmark Inc. Has $12.01 Million Holdings in IDEXX Laboratories, Inc. (IDXX)

Share on StockTwits

Assetmark Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 48,112 shares of the company’s stock after selling 2,042 shares during the period. Assetmark Inc.’s holdings in IDEXX Laboratories were worth $12,012,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Highbridge Capital Management LLC lifted its holdings in IDEXX Laboratories by 1,033.3% during the third quarter. Highbridge Capital Management LLC now owns 17,000 shares of the company’s stock valued at $4,244,000 after purchasing an additional 15,500 shares in the last quarter. AlphaStar Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth $202,000. Maryland Capital Management purchased a new position in shares of IDEXX Laboratories in the third quarter worth $225,000. Kepos Capital LP lifted its holdings in shares of IDEXX Laboratories by 5.0% in the third quarter. Kepos Capital LP now owns 17,808 shares of the company’s stock worth $4,446,000 after buying an additional 851 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in shares of IDEXX Laboratories by 567.0% in the third quarter. Kornitzer Capital Management Inc. KS now owns 132,836 shares of the company’s stock worth $33,164,000 after buying an additional 112,920 shares in the last quarter. 91.14% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Rebecca M. Henderson sold 3,504 shares of the business’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $194.92, for a total value of $682,999.68. Following the sale, the director now owns 22,200 shares in the company, valued at $4,327,224. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jacqueline Studer sold 3,313 shares of the business’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $201.27, for a total transaction of $666,807.51. The disclosure for this sale can be found here. Insiders own 2.56% of the company’s stock.

Several equities analysts have recently commented on IDXX shares. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Canaccord Genuity lowered their target price on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, November 5th. Bank of America lowered their target price on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Credit Suisse Group boosted their target price on shares of IDEXX Laboratories from $255.00 to $259.00 and gave the stock an “outperform” rating in a report on Friday, August 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. IDEXX Laboratories currently has an average rating of “Buy” and an average target price of $252.33.

IDXX stock opened at $190.01 on Friday. IDEXX Laboratories, Inc. has a one year low of $154.88 and a one year high of $256.22. The firm has a market capitalization of $16.97 billion, a PE ratio of 57.93, a P/E/G ratio of 2.50 and a beta of 0.84.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, November 1st. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a net margin of 15.19% and a negative return on equity of 994.76%. The company had revenue of $545.00 million for the quarter, compared to analysts’ expectations of $545.66 million. During the same quarter in the previous year, the business posted $0.76 earnings per share. IDEXX Laboratories’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 4.19 EPS for the current fiscal year.

WARNING: This story was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://baseballnewssource.com/2018/12/08/assetmark-inc-has-12-01-million-holdings-in-idexx-laboratories-inc-idxx/3063872.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.